CAMBRIDGE, MA-Ipsen has announced plans to relocate its US research and development operations from Milford, MA to Cambridge—a hub for biotechnology research. This site will be key for innovation in targeted therapies across Ipsen’s specialty areas as well as a center of excellence for peptides (a medicine type), according to the company. The move also brings Ipsen closer to several key partners based in the Cambridge area, including prominent hospitals, medical schools, biotech companies and universities,
The company signed an eleven-year lease on 62,600 rentable square-feet of laboratory and office space within a 282,000 square-foot building, located at 650 E. Kendall Street. The deal was brokered by Cresa Corporate Real Estate‘s Adam Subber, principal. The property is owned by BioMed Realty Trust Inc.